Drug
DSP-7888
DSP-7888 is a pharmaceutical drug with 3 clinical trials. Historical success rate of 100.0%.
Total Trials
3
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 2 completed trials
Completion Rate
100%(2/2)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Phase Distribution
Ph phase_1
2
67%
Ph phase_2
1
33%
Phase Distribution
2
Early Stage
1
Mid Stage
0
Late Stage
Phase Distribution3 total trials
Phase 1Safety & dosage
2(66.7%)
Phase 2Efficacy & side effects
1(33.3%)
Highest Phase Reached
Phase 2Trial Status & Enrollment
Completion Rate
100.0%
2 of 2 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
0
trials recruiting
Total Trials
3
all time
Status Distribution
Completed(2)
Other(1)
Detailed Status
Completed2
unknown1
Development Timeline
Analytics
Development Status
Total Trials
3
Active
0
Success Rate
100.0%
Most Advanced
Phase 2
Trials by Phase
Phase 12 (66.7%)
Phase 21 (33.3%)
Trials by Status
completed267%
unknown133%
Recent Activity
0 active trials
Showing 3 of 3
completedphase_1
A Study of DSP-7888 in Pediatric Patients With Relapsed or Refractory High Grade Gliomas
NCT02750891
completedphase_1
Study of DSP-7888 in Patients With Myelodysplastic Syndrome
NCT02436252
unknownphase_2
Investigator-initiated Clinical Trial (Phase II) of Cancer Vaccine "Dainippon Sumitomo Phama(DSP)-7888" for Acute Myeloid Leukemia Patients.
NCT04747002
Clinical Trials (3)
Showing 3 of 3 trials
NCT02750891Phase 1
A Study of DSP-7888 in Pediatric Patients With Relapsed or Refractory High Grade Gliomas
NCT02436252Phase 1
Study of DSP-7888 in Patients With Myelodysplastic Syndrome
NCT04747002Phase 2
Investigator-initiated Clinical Trial (Phase II) of Cancer Vaccine "Dainippon Sumitomo Phama(DSP)-7888" for Acute Myeloid Leukemia Patients.
All 3 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 3